Comparative Guide to ICH E2A through E2F for Safety Reporting
The E2 guidelines are intended to harmonize safety reporting procedures worldwide. Each module focuses on a different aspect of clinical safety:
Click to read the full article.
Regulatory Guidelines
EMA Guidelines for Clinical Trials and Drug Approvals: A Complete Overview
Founded in 1995, the EMA harmonizes the work of national regulatory agencies within the European Economic Area (EEA). It offers centralized review procedures, scientific advice, and post-approval monitoring, fostering efficient access to medicines while protecting public health. Navigating EMA regulatory processes requires a deep understanding of clinical trial regulations, marketing authorization pathways, and post-marketing obligations.
Click to read the full article.
ICH E9(R1) Addendum: Estimands and Sensitivity Analysis in Clinical Trials
An estimand is a precise description of the treatment effect to be estimated in a clinical trial. It connects the study’s objective with the statistical analysis strategy. The estimand clarifies how different post-randomization events—especially intercurrent events—are handled when measuring the treatment effect. This allows for greater transparency and consistency across studies.
Click to read the full article.
U.S. FDA Regulations for Clinical Trials and Drug Approvals: A Complete Guide
The FDA’s regulatory authority covers drugs, biologics, medical devices, and more, spanning from preclinical testing through post-marketing surveillance. By establishing clear guidelines and review processes, the FDA protects public health while fostering innovation. Complying with FDA regulations not only facilitates market access in the U.S. but also enhances global credibility for sponsors.
Click to read the full article.
Understanding ICH E8(R1) on Clinical Trial Quality and Efficiency
Originally adopted in 1997, ICH E8 provided general considerations for clinical trials. With the evolution of trial complexity—ranging from personalized medicine to decentralized models—a revised framework was required to ensure both quality and regulatory compliance. Released in 2021, ICH E8(R1) aligns with other guidelines like E6(R3) and E17, promoting a harmonized approach to trial conduct across global jurisdictions.
Click to read the full article.
ICH E6(R3): Major Updates and What They Mean for Clinical Trials
The current ICH E6(R2) guidance was adopted in 2016 and primarily addressed electronic systems and sponsor oversight. However, as clinical trials rapidly advanced into digital and decentralized formats, it became evident that a broader framework was necessary. The emergence of technologies like eConsent, remote monitoring, and real-world data called for a more agile, principle-based model of GCP.
Click to read the full article.
EMA Regulatory Requirements for Herbal Medicines: A Detailed Overview
While herbal products are derived from natural sources, the assumption that they are inherently safe is misleading. Active ingredients in plant-derived products can cause pharmacological effects, interact with other drugs, or lead to adverse events. The European Medicines Agency (EMA) ensures that herbal products meet the same high standards applied to conventional pharmaceuticals under EU directives and regulations.
Click to read the full article.
EMA Regulatory Requirements for Herbal Medicines: A Complete Guide
The regulation of herbal medicines in the EU is primarily governed by Directive 2004/24/EC, which amended Directive 2001/83/EC. This legal framework introduced a specific regime for traditional herbal medicinal products, known as the Traditional Herbal Medicinal Products Directive (THMPD).
Click to read the full article.
WHO Guidelines for Clinical Trials and Global Drug Approvals: A Complete Overview
Established in 1948, the WHO serves as the leading international authority on public health. Through its normative guidelines, technical reports, and global programs, WHO sets scientific and ethical standards for clinical research, product evaluation, vaccine prequalification, and emergency health responses. WHO’s guidance supports regulatory authorities, researchers, and sponsors in achieving consistency, quality, and equity across healthcare systems globally.
Click to read the full article.
FDA Guidance on Quality Metrics Program: Enhancing Pharmaceutical Compliance
The FDA first introduced the concept of quality metrics in 2013 as a tool to monitor product and process quality and promote innovation. Following industry feedback and pilot studies, the agency released a revised draft guidance titled “Submission of Quality Metrics Data” in 2016 and further clarified expectations in subsequent updates.
Click to read the full article.